Slide 1: PIPE-791 Phase 1b PET Trial Topline Data Supplemental Information
©) contiNeum therapeutics PIPE-791 Phase 1b PET Trial Topline Data Supplementa Information September 18, 2025 ~~
Slide 2: Disclaimer
Disclaimer ‘is presentation by Contineum Teropetis, ne. "Comineun, “We” ot “ut contains erwerdockng stotements, Al sateen other hon sotements ofits contained inthis resentation, Incing without Imitation ttements egorsng ou tre rest of operations ond tran! postion hue revenue, timing progress ord exp
Slide 3: A Phase 1b, Open-Label Trial of PIPE-791 to Evaluate Brain and Lung LPA1 Receptor Occupancy
A Phase 1b, Open-Label Trial of PIPE-791 to Evaluate Brain and Lung Lysophosphatidic Acid 1 (LPA1) Receptor Occupancy + Evaluated LPAI receptor occupancy (RO) as assessed by changes from baseline in LPA1 PET tracer uptake, ‘after single-dose administration of PIPE-791, confirming LPA1 target engagem
Slide 4: PIPE-791 Phase 1b PET Trial Topline Results
PIPE-791 Phase 1b PET Trial Topline Results P°F]-PIPE-497 Clinical LPA1R PET + P®F]-PIPE-497 (LPAL) PET tracer binding showed broad distribution in the CNS consistent with expected glial expression + PIPE-791 dose-dependently reduced PET tracer uptake confirming LPAI target engagement Sign decrease
Slide 5: PIPE-791-101 Phase 1 HV: SAD vs. MAD Exposures
PIPE-791-101 Phase 1 HV: SAD vs. MAD Exposures") 10000: 1000-4 100 PIPE-791 (ngimL) 104 : —} —s PET trial ~ 90% RO* Be tai BRS! (0) meer neon ction T 3 6 9 12 15 18 T T T T T Time Since Dosing (in hours) 260m rete 11mg MAD, D1 11mg MAD, 07 ‘3 mg MAD, D7 10 mg MAD, D14 \contineum
Slide 6: Poor PET Tracer Uptake in Healthy Volunteer Lungs
Poor PET Tracer Uptake in Healthy Volunteer Lungs + [F]-PIPE-497 demonstrated very low, homogenous lung binding at baseline * Reflects low LPA1 receptor expressior this tissue compartment healthy lungs as well as methodological difficulties for * Due to low baseline binding, it’s challenging to obta
Slide 7: LPA1 Receptor Expression Significantly Lower in Healthy Lungs
LPA1 Receptor Expression Significantly Lower in Healthy Lungs IPF Donor Lung Sections * Healthy control lung - poor binding signal due to low LPAI receptor expression 2 La * IPF lung - robust binding signal due to high LPAI receptor expression * Ex vivo autoradiographic results explain the poor trac
Slide 8: Excellent Relationship Between Brain and Lung RO and Drug Levels
Excellent Relationship Between Brain and Lung RO and Drug Levels In vivo mouse brain and lung RO Brain RO to Lung RO Correlation’) Brain to Lung PIPE-781 Correlation) R squared 085 awe ‘Slope 103, ae Romeres 120 3 oo. Boa oo Brain LPAT RO Based on the distribution pattern of PIPE-791, we believe the
Slide 9: PIPE-791 Phase 1b PET Trial Topline Data Supplemental Information
©) contiNeum therapeutics PIPE-791 Phase 1b PET Trial Topline Data Supplementa Information September 18, 2025 ~~